Chronic Obstructive Pulmonary Disease | Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease research study
What is the primary objective of this study?
COPD is a progressive pulmonary disease that is characterized by an inflammatory process in the airways and the lungs which leads to progressive airway obstruction. The inflammation is associated with tissue loss and remodelling. The investigators hypothesized that doxycycline reduces neutrophilic airway inflammation in patients with COPD. Therefore the investigators will conduct a randomized trial of doxycycline in 30 patients.
Who is eligible to participate?
Inclusion Criteria: - GOLD II or III COPD (GOLD II: FEV1/FVC < 70%; 50% < FEV1 < 80% predicted, GOLD III: FEV1/FVC < 70%; 30% < FEV1 < 50% predicted ). - Stable disease (no exacerbations in the last 3 months). - Age > 40 yrs. - Written informed consent. Exclusion Criteria: - Infections and/or use of antibiotics in the last month. - Bacterial colonization of the airways, proven by sputum cultures or broncho-alveolar lavage (BAL). - Allergy for tetracyclines or a history of substantial side-effects. - Active respiratory diseases other than COPD (e.g. sarcoidosis, tuberculosis, lung cancer, bronchiectasis). - Acute exacerbation of COPD as defined by Anthonisen et al. . - Signs and/or symptoms of a current respiratory or non-respiratory infection. - Use of oral or intravenous corticosteroids or other immunosuppressive drugs within the last month.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Chronic Obstructive Pulmonary Disease
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:DoxycyclineDoxycycline tablets, 100mg daily
Drug:PlaceboPlacebo tablets 100mg
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
1Doxycycline 100mg daily
Start Date: April 2009
Completed Date: January 2010
Phase: Phase 4
Primary Outcome: myeloperoxidase in induced sputum
Secondary Outcome: MMP-8, MMP-9, IL-6 levels and differential cell counts in induced sputum.
Study sponsors, principal investigator, and references
Lead Sponsor: Medical Center Alkmaar
Collaborator: Leiden University Medical Center